Zemcelpro Receives NUB Status 1 in Germany, Enabling Immediate Hospital Reimbursement Applications
核心洞察
Zemcelpro (dorocubicel), a novel stem cell therapy for blood cancers (搜索), has been granted NUB Status 1 in Germany, allowing hospitals to apply for temporary supplementary reimbursement.
The designation reflects recognition of the therapy's clinical evidence base, with 220 German hospitals expressing interest in accessing the treatment for 2026.
The therapy addresses unmet medical needs in allogeneic haematopoietic stem cell transplantation for patients with life-threatening blood cancers (搜索) who have limited therapeutic options.
ExCellThera (搜索) Inc. and its wholly owned subsidiary Cordex Biologics (搜索) announced that Zemcelpro (dorocubicel), also known as UM171 Cell Therapy, has been granted Status 1 listing by Germany's NUB (Neue Untersuchungs- und Behandlungsmethoden) program. The designation enables hospitals to immediately apply for temporary, supplementary reimbursement for the therapy's use while broader reimbursement pathways continue to be evaluated.
The NUB designation represents recognition that Zemcelpro is supported by a relevant and growing body of clinical evidence. Notably, 220 hospitals across Germany have expressed interest in accessing the therapy through the NUB mechanism for the 2026 calendar year.
Clinical Significance and Patient Population
"NUB Status 1 represents a significant milestone for ExCellThera (搜索) and Cordex and reflects both the innovative nature of Zemcelpro (dorocubicel) and its benefit in addressing a pressing unmet medical need in allogeneic haematopoietic stem cell transplantation," said David Millette, CEO of ExCellThera. "Under its initial label, Zemcelpro (dorocubicel) is indicated for patients with life threatening blood cancers (搜索) who have limited therapeutic options."
Zemcelpro has recently received conditional marketing authorization from the European Commission for the treatment of adults with haematological malignancies (搜索) requiring allogeneic haematopoietic stem cell transplantation following myeloablative conditioning, for whom no other suitable donor cells are available.
Clinical Development and Evidence Base
Zemcelpro has been evaluated in 120 patients with haematologic malignancies in clinical trials across the United States, Europe and Canada. The therapy has been tested in Phase 2 trials in patients with high and very high-risk acute leukemias (搜索) and myelodysplasias (搜索) who have limited treatment options with low survival outcomes and high incidence of relapse under current standard of care.
The patient population includes those with TP53 (搜索) mutations or other genetic abnormalities, patients requiring a second transplant, and patients with refractory or active disease. A pivotal Phase 3 trial in this patient population will be initiated as soon as possible.
Regulatory Recognition and Future Plans
The therapy has received multiple regulatory designations, including orphan drug designation and regenerative medicine advanced therapy (RMAT) designations from the FDA, as well as orphan medicinal product designation, advanced therapy medicinal product (ATMP) classification and priority medicines (PRIME) designation from the EMA.
Additional regulatory filings are planned for Zemcelpro with other health authorities, including in the US, Canada, the UK, and Switzerland. The use of the therapy in other patient populations, including pediatric patients and patients with non-malignant haematological diseases, is also being investigated.
Commercial Strategy and Market Access
With NUB status 1 in place, Cordex will work closely with leading German stem cell transplant centers to support individual NUB applications and further expand clinical adoption. The company will invest in post-market registry participation and evidence and economic data generation to support longer-term reimbursement and inclusion in clinical guidelines.
Cordex is actively seeking strategic partnerships to support and accelerate the commercialization of Zemcelpro in Europe and other international markets. The company is engaging with national health authorities to enable early access for eligible patients and establishing a future network of treatment sites for therapy administration.
Technology Platform
Zemcelpro is a novel personalized cryopreserved haematopoietic stem cell transplantation product containing two components: UM171-expanded CD34+ (搜索) cells (dorocubicel) and unexpanded CD34- cells, each derived from the same cord blood unit. The therapy is based on ExCellThera (搜索)'s proprietary Enhance platform, which includes the proprietary molecule UM171 with a first-in-class mechanism of action for ex vivo expansion and metabolic fitness of haematopoietic stem cells (搜索).